July 21, 2017. We support many of the methodological proposals included in USPSTF’s draft research plan to study the impact of interventions to prevent and reduce tobacco and nicotine use in children and adolescents. However, the draft approach would not evaluate the effectiveness of specific types of interventions on subgroups of children and adolescents. We strongly recommend making the above changes to strengthen the utility of the research findings that USPSTF will rely on for its recommendations.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Letter to Mayor Bowser Regarding Toxic Artificial Turf
July 19, 2017. As our mayor, I urge you to safeguard our children and athletes by requiring safer athletic fields and playgrounds. At this point, there are no synthetic materials that are proven to be as safe as natural grass.
Read More »NCHR Testimony at FDA on the Hatch-Waxman Amendments
July 18, 2017. We hope FDA will follow the Commissioner’s recommended course of action to further improve this system for the future benefit of patients and industry alike.
Read More »NCHR Testimony at FDA Advisory Committee Oncology Meeting on Mylotarg (“GO”)
July 12, 2017. Given the research design, only one pivotal study, the lack of U.S. patients, and a less than convincing literature review, the data do not support sufficient support for approval. The studies, in our view, do not provide strong evidence that GO is effective and there are still continuing safety concerns.
Read More »NCHR Comment on the USPSTF’s Draft Recommendations for Syphilis Screening in Pregnancy
July 5, 2017. In conclusion, we strongly support the USPSTF’s ongoing effort to provide screening recommendations based on current, quality scientific studies. We hope the review will cover differences in clinical practice and the diversity of populations to help the USPSTF make meaningful recommendations for syphilis screening in pregnant women.
Read More »